CytoMed Therapeutics Limited Ordinary Shares (GDTC) — Defensive Interval Ratio
CytoMed Therapeutics Limited Ordinary Shares (GDTC) has a Defensive Interval Ratio of 53 days as of December 2025. Defensive assets of $103.86K (cash $-, short-term investments $-, receivables $103.86K) cover 53 days of daily cash needs of $1.94K/day.
Defensive Interval Ratio
Defensive Assets
Daily Cash Need
Current Liabilities
CytoMed Therapeutics Limited Ordinary Shares Defensive Interval Ratio (2019–2025)
This chart shows how CytoMed Therapeutics Limited Ordinary Shares's Defensive Interval Ratio has evolved across 7 annual periods from 2019 to 2025. As of December 2025, the ratio stands at 53 days, meaning defensive assets of $103.86K can fund 53 days of operations without new revenue. For the complete balance sheet picture, see GDTC current and non-current assets.
Annual Defensive Interval Ratio for CytoMed Therapeutics Limited Ordinary Shares (2019–2025)
The table below presents the year-by-year Defensive Interval Ratio for CytoMed Therapeutics Limited Ordinary Shares from 2019 to 2025, covering 7 annual filings. Each row shows defensive assets, daily cash need, the DIR in days, and the change in days compared to the prior year. See CytoMed Therapeutics Limited Ordinary Sh (GDTC) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
| Year | DIR (days) | Defensive Assets (USD) | Daily Cash Need | Cash | ST Investments | Change (days) |
|---|---|---|---|---|---|---|
| 2025 | 53 days | $103.86K | $1.94K/day | $- | $- | ▼ -78 days |
| 2024 | 132 days | $219.13K | $1.66K/day | $- | $200.35K | ▲ +4 days |
| 2023 | 128 days | $251.94K | $1.97K/day | $- | $47.19K | ▲ +122 days |
| 2022 | 6 days | $66.10K | $11.46K/day | $- | $11.56K | ▲ +2 days |
| 2021 | 4 days | $30.49K | $8.06K/day | $- | $15.27K | ▼ -33 days |
| 2020 | 37 days | $273.16K | $7.48K/day | $- | $43.59K | ▼ -46 days |
| 2019 | 82 days | $84.80K | $1.03K/day | $- | $84.80K | — |